Navegando por Palavras-chave "inflammatory"
Agora exibindo 1 - 4 de 4
Resultados por página
Opções de Ordenação
- ItemAcesso aberto (Open Access)Anti-inflammatory and antinociceptive activities of Euterpe oleracea Mart., Arecaceae, oil(Sociedade Brasileira de Farmacognosia, 2011-02-01) Favacho, Hugo Alexandre Silva; Oliveira, Bianca R.; Santos, Kelem Costa dos; Medeiros, Benedito Junior Lima de; Sousa, Pergentino Jose da Cunha; Perazzo, Fábio Ferreira [UNIFESP]; Carvalho, José Carlos Tavares; Universidade Federal do Amapá Laboratório de Pesquisa em Fármacos; Universidade Federal do Pará Faculdade de Farmácia Programa de Pós-graduação em Ciências Farmacêuticas; Universidade Federal do Pará Faculdade de Farmácia Laboratório de Farmacodinâmica; Universidade Federal de São Paulo (UNIFESP)The oil of the fruits of Euterpe oleracea Mart., Arecaceae (OEO), was evaluated in models of inflammation and hyperalgesia in vivo to study its effects on these conditions. The experimental models contained the writhing test in mice, rat paw edema, granuloma test in rats, vascular permeability in rats, cell migration to the peritoneal cavity in rats and ear erythema induced by croton oil in mice. Doses of 500, 1000 and 1500 mg/kg of OEO were administered orally. The observed number of writhes was inhibited by 33.67, 45.88 and 55.58%, respectively. OEO produced a dose-dependent effect, with linear correlation coefficient R=0.99 (y=0.0219x+23.133), and the median effective dose found was 1226.8 mg/kg. The oral administration of 1226.8 mg/kg of OEO inhibited carrageenan-induced edema by 29.18% (p<0.05) when compared to the control group. The daily administration of OEO for six days inhibited the formation of granulomatous tissue by 36.66% (p<0.01). In ear erythema induced by croton oil, OEO presented a significant inhibition (37.9%). In the vascular permeability test, treatment with OEO decreased the response to histamine, inhibiting vascular permeability by 54.16%. In carrageenan-induced peritonitis, OEO reduced the number of neutrophils migrating compared to the control group by 80.14%. These results suggested that OEO has anti-inflammatory and antinociceptive activities, probably of peripheral origin and linked to prostaglandin biosynthesis inhibition.
- ItemAcesso aberto (Open Access)Baixa dose de methotrexate comparado a placebo em osteoartrite de joelho(Sociedade Brasileira de Reumatologia, 2007-10-01) Holanda, Haroldo Tenório De [UNIFESP]; Pollak, Daniel Feldman [UNIFESP]; Pucinelli, Mário Luis Cardoso [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)OBJECTIVE: to evaluate the efficacy of low-dose methotrexate in the treatment of knee osteoarthritis. METHODS: 58 patients were separated into two groups in a prospective, double-blinded, placebo-controlled, randomized 4 months study. Group 1 received a 7,5 mg weekly dose of methotrexate whilst group 2 received placebo. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Lequèsne Algofunctional Index and the Visual Analogue Scale (VAS) for pain were utilized as measurement of primary evaluation. The quantity of paracetamol used for analgesia served as a secondary evaluation. RESULTS: the patient s average age was of 60.4 years in the group 2 and 61.8 years in group 1 (p = 0.43). In both groups, women predominated, comprising 93.1% in group 1 and 72.4% in group 2 (p = 0.08). There were no statistically significant difference between both groups regarding WOMAC (p = 0.94), Lequèsne (p = 0.87) and VAS (p = 0.89. Likewise, in the paracetamol consumption there was not statistically significant difference between both groups. However, there was tendency to increased consumption in the placebo group. CONCLUSION: methotrexate provided neither symptomatic relief nor did it reduce the functional limitation when compared to placebo in knee osteoarthritis. Methotrexate showed a tendency to decrease the consumption of paracetamol in knee osteoarthritis.
- ItemSomente MetadadadosCervical cerclage placement decreases local levels of proinflammatory cytokines in patients with cervical insufficiency(Mosby-Elsevier, 2017) Monsanto, Stephany P.; Daher, Silvia [UNIFESP]; Ono, Erika [UNIFESP]; Tezotto Pendeloski, Karen Priscilla [UNIFESP]; Traina, Evelyn [UNIFESP]; Mattar, Rosiane [UNIFESP]; Tayade, ChandrakantBACKGROUND: Cervical insufficiency is characterized by premature, progressive dilation and shortening of the cervix during pregnancy. If left unattended, this can lead to the prolapse and rupture of the amniotic membrane, which usually results in midtrimester pregnancy loss or preterm birth. Previous studies have shown that proinflammatory cytokines such as interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor alpha are up-regulated in normal parturition but are also associated with preterm birth. Studies evaluating such markers in patients with cervical insufficiency have evaluated only their diagnostic potential. Even fewer studies have studied them within the context of cerclage surgery. OBJECTIVES(S): The objective of the study was to evaluate the impact of local and systemic inflammatory markers on the pathogenesis of cervical insufficiency and the effect of cerclage surgery on the local immune microenvironment of women with cervical insufficiency. STUDY DESIGN: We recruited 28 pregnant women (12- 20 weeks' gestation) diagnosed with insufficiency and referred for cerclage surgery and 19 gestational age-matched normal pregnant women as controls. Serum and cervicovaginal fluid samples were collected before and after cerclage surgery and during a routine checkup for normal women and analyzed using a targeted 13-plex proinflammatory cytokine assay. RESULTS: Before surgery, patients with cervical insufficiency had higher levels of interleukin-1b, interleukin-6, interleukin-12, monocyte chemoattractant protein-1 and tumor necrosis factor alpha in cervicovaginal fluid compared to controls, but after surgery, these differences disappeared. No differences were found in serum of insufficiency versus control women. In patients with insufficiency, the levels of interleukin-1b, interleukin-6, interleukin-8, monocyte chemoattractant protein-1, and interferon gamma in cervicovaginal fluid declined significantly after cerclage compared with before intervention, but these changes were not detected in serum. CONCLUSION: Compared with normal women, patients with cervical insufficiency have elevated levels of proinflammatory cytokines in cervicovaginal fluid but not in serum, suggesting a dysregulation of the local immune environment. Cerclage intervention led to a significant decline in these proinflammatory cytokines, suggesting that cerclage may help reduce local inflammation in cervical insufficiency.
- ItemSomente MetadadadosINTRAVITREAL BEVACIZUMAB for INFLAMMATORY CHOROIDAL NEOVASCULARIZATION Results from the Pan-American Collaborative Retina Study Group at 24 Months(Lippincott Williams & Wilkins, 2011-02-01) Arevalo, J. Fernando; Adan, Alfredo; Berrocal, Maria H.; Espinoza, Juan V.; Maia, Mauricio [UNIFESP]; Wu, Lihteh; Roca, Jose A.; Quiroz-Mercado, Hugo; Ruiz-Moreno, Jose M.; Serrano, Martin A.; Pan-Amer Collaborat Retina Study; Edif Ctr Caracas PH 1; Hosp Clin Barcelona; Univ Puerto Rico; Universidade Federal de São Paulo (UNIFESP); Inst Cirugia Ocular; Clin Ricardo Palma; Hosp Dr Luis Sanchez Bulnes; Inst Oftalmol Alicante; Miguel Hernandez UnivBackground: To evaluate the anatomical and functional outcomes of intravitreal bevacizumab (1.25 or 2.5 mg) in the treatment of inflammatory choroidal neovascularization at 24 months.Methods: We reviewed the clinical records of 22 consecutive patients (23 eyes) with choroidal neovascularization secondary to chorioretinal inflammatory disease in this interventional retrospective multicenter case series. Sixteen eyes (63.6%) received a dose of 1.25 mg of intravitreal bevacizumab, and 7 eyes (36.4%) received a dose of 2.5 mg of intravitreal bevacizumab.Results: At baseline, the mean best-corrected visual acuity was 0.68 logarithm of minimum angle of resolution (Early Treatment Diabetic Retinopathy Study chart = 20/100). After intravitreal bevacizumab, best-corrected visual acuity improved significantly to 0.41 logarithm of minimum angle of resolution (20/51), 0.42 logarithm of minimum angle of resolution (20/53), and 0.40 logarithm of minimum angle of resolution (20/50) at 6, 12, and 24 months, respectively (P < 0.05). Fourteen eyes (60.8%) received 1 injection. Central macular thickness by optical coherence tomography decreased from 375.3 mu m (range: 240-634 mu m) at baseline to 241.6 mu m (range: 189-306 mu m) at 24 months of follow-up (P < 0.0001).Conclusion: Intravitreal bevacizumab at doses of 1.25 mg and 2.5 mg seems to provide stability or improvement in best- corrected visual acuity, optical coherence tomography, and fluorescein angiogram in inflammatory choroidal neovascularization at 24 months. All patients were treated after the underlying uveitic condition was controlled.RETINA 31: 353-363, 2011